Lineage Cell Therapeutics Inc (AMEX: LCTX) is 37.21% higher on its value in year-to-date trading and has touched a low of $0.48 and a high of $1.61 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LCTX stock was last observed hovering at around $0.60 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $0.69, the stock is 14.78% and 19.69% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.17 million and changing 14.78% at the moment leaves the stock -19.84% off its SMA200. LCTX registered -25.87% loss for a year compared to 6-month loss of -28.48%. The firm has a 50-day simple moving average (SMA 50) of $0.5806 and a 200-day simple moving average (SMA200) of $0.8629.
The stock witnessed a 37.21% gain in the last 1 month and extending the period to 3 months gives it a -19.09%, and is 12.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.03% over the week and 9.71% over the month.
Lineage Cell Therapeutics Inc (LCTX) has around 75 employees, a market worth around $151.98M and $8.72M in sales. Profit margin for the company is -230.66%. Distance from 52-week low is 43.35% and -57.17% from its 52-week high. The company has generated returns on investments over the last 12 months (-29.66%).
with sales reaching $1.62M over the same period.The EPS is expected to grow by 8.33% this year, but quarterly earnings will post -7.73% year-over-year. Quarterly sales are estimated to shrink -23.46% in year-over-year returns.
Lineage Cell Therapeutics Inc (LCTX) Top Institutional Holders
143.0 institutions hold shares in Lineage Cell Therapeutics Inc (LCTX), with institutional investors hold 50.79% of the company’s shares. The shares outstanding are 220.42M, and float is at 219.47M with Short Float at 12.35%. Institutions hold 50.56% of the Float.
The top institutional shareholder in the company is BROADWOOD CAPITAL INC with over 41.67 million shares valued at $41.55 million. The investor’s holdings represent 22.7798% of the LCTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.56 million shares valued at $9.53 million to account for 5.2264 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 8.47 million shares representing 4.6329% and valued at over $8.45 million, while DEFENDER CAPITAL, LLC. holds 2.7188 of the shares totaling 4.97 million with a market value of $4.96 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
The most recent transaction is an insider purchase by BROADWOOD PARTNERS, L.P., the company’s Director. SEC filings show that BROADWOOD PARTNERS, L.P. bought 7,894,737 shares of the company’s common stock on Jan 27 ’25 at a price of $0.76 per share for a total of $6.0 million. Following the purchase, the insider now owns 49.56 million shares.
Lineage Cell Therapeutics Inc disclosed in a document filed with the SEC on Nov 26 ’24 that Howe Jill Ann (Chief Financial Officer) bought a total of 15,000 shares of the company’s common stock. The trade occurred on Nov 26 ’24 and was made at $0.59 per share for $8850.0. Following the transaction, the insider now directly holds 25500.0 shares of the LCTX stock.
Still, SEC filings show that on Nov 26 ’24, Samuel George A. III (General Counsel) acquired 15,000 shares at an average price of $0.60 for $9000.0. The insider now directly holds 22,184 shares of Lineage Cell Therapeutics Inc (LCTX).
